# Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO…

- Source: PR Newswire
- Published: 2026-10-25T15:31:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/positive-overall-survival-results-from-the-phase-iii-harmoni-gi1-trial-of-ivonescimab-plus-chemotherapy-versus-durvalumab-plus-chemotherapy-in-first-line-biliary-tract-cancer-presented-at-the-esmo-2026-presidential-symposium-302918768.html
- Canonical: https://groundlevelnews.com/story/positive-overall-survival-results-from-the-phase-iii-harmoni-gi1-trial-9c9857/

HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase III HARMONi-GI1 trial (AK112-309). The study evaluated first-in-class ivonescimab plus...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._